Literature DB >> 16799049

Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.

Reinhard Werth1, Gereon Schädler.   

Abstract

PURPOSE: In adult patients and in children of school age who have been treated with vigabatrin (VGB), persistent visual field defects have been reported as a side effect. To date, it is unknown to what extent VGB causes visual field loss in young children and mentally handicapped adolescents who cannot be tested with conventional perimetric
METHODS: The purpose of the present study was to investigate VGB-induced visual field loss in these patients by using a noncommercial arc perimeter and a forced-choice, preferential-looking method. The visual field size was measured in 30 patients aged 1 to 15 years who had epilepsy and who were treated with VGB. The visual field of these patients was compared to the visual field of 70 control subjects.
RESULTS: In eight (27%) patients who had been treated with VGB, the visual field was constricted compared with the visual field of the children belonging to the control group.
CONCLUSIONS: Arc perimetry shows that mentally handicapped patients and children younger than 6 years treated with VGB have visual field loss compared with the loss reported in adult patients receiving VGB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799049     DOI: 10.1167/iovs.05-0778

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  2 in total

1.  Retinal defect in children with infantile spasms of varying etiologies: An observational study.

Authors:  Michelle T McFarlane; Tom Wright; Blathnaid McCoy; O Carter Snead; Carol A Westall
Journal:  Neurology       Date:  2019-12-02       Impact factor: 9.910

2.  Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.

Authors:  Carol A Westall; Tom Wright; Filomeno Cortese; Ananthavalli Kumarappah; O Carter Snead; Joseph R Buncic
Journal:  Neurology       Date:  2014-11-07       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.